Latest net tangible assets for CDTX: $420M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2025), CDTX shows a net tangible assets of $420M. That compares with $120M in the prior-year period — up 265.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CDTX's net tangible assets is now $420M (was $120M) — a 265.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cidara Therapeutics is outperforming or lagging.
Tracking CDTX's net tangible assets over time shows whether Cidara Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $420M That compares with $120M in the prior-year period — up 265.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Cidara Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $420M) with ownership activity and broader fundamentals.
Cidara Therapeutics's net tangible assets is $420M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.